Zai Lab Limited Unsponsored ADR $ZLAB Stock Position Boosted by Headlands Technologies LLC

Headlands Technologies LLC increased its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 142.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,010 shares of the company’s stock after buying an additional 39,901 shares during the quarter. Headlands Technologies LLC owned about 0.06% of Zai Lab worth $1,292,000 at the end of the most recent reporting period.

Separately, Royal Bank of Canada grew its position in Zai Lab by 214.3% during the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock worth $498,000 after purchasing an additional 9,390 shares in the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Stock Performance

Shares of ZLAB opened at $25.46 on Tuesday. The business’s fifty day moving average price is $21.44 and its two-hundred day moving average price is $20.17. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -14.89 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $34.72.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.The firm had revenue of $106.31 million for the quarter. As a group, research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZLAB shares. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Wall Street Zen cut Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup upped their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zai Lab currently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Insiders Place Their Bets

In other Zai Lab news, CFO Yajing Chen sold 2,264 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44. Following the sale, the chief financial officer directly owned 35,691 shares in the company, valued at approximately $623,164.86. This trade represents a 5.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William Lis sold 8,506 shares of Zai Lab stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the transaction, the director directly owned 41,931 shares in the company, valued at approximately $1,048,275. The trade was a 16.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 50,258 shares of company stock worth $960,741 over the last ninety days. 4.88% of the stock is currently owned by corporate insiders.

Zai Lab Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.